NCT04952792View on ClinicalTrials.gov

Study of Apixaban in Patients Receiving Hemodiafiltration

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Atrial FibrillationHemodialysis Complication
Interventions
DRUG

Apixaban 2.5 milligram Oral Tablet

Apixaban 2.5mg/12h, oral, 28 days

Trial Locations (1)

08907

Carolina Polo, Barcelona

All Listed Sponsors
collaborator

Spanish Society of Nephrology

OTHER

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Hospital Universitari de Bellvitge

OTHER